Lung Cancer

Immune Checkpoint Inhibitors March to First-Line Treatment in Advanced NSCLC

For the majority of patients who are diagnosed with advanced-stage non–small cell lung cancer (NSCLC), platinum-based doublets have been the standard of care for over 30 years. Recently,...

Hematologic Malignancies

Novel Agents on the Horizon in Lymphoma

Attendees at the 2016 Pan Pacific Lymphoma Conference held July 18–22 in Koloa, Hawaii, got a peek at early data for a number of novel agents in the treatment of various lymphoma subtypes.

Gastrointestinal Cancer

Does Colonoscopy Screening in Older Adults Prevent Colorectal Cancer?

A large population-based observational study by García-Albéniz et al evaluating the effectiveness and safety of screening colonoscopy for the prevention of colorectal cancer in people aged 70...


More Top Stories

Palliative Care

Charles F. von Gunten, MD, PhD, on Referrals for Hospice Care: A Quality Improvement Approach

James Morgan, PhD, Named Scientific Director at St. Jude

St. Jude Children’s Research Hospital has named James Morgan, PhD, Scientific Director and Executive Vice President. Dr. Morgan held the Interim Scientific Director post since 2015 and was formerly Chair of the Department of Developmental Neurobiology.

As Scientific Director, Dr. Morgan will...


ASTRO 2016: Hypofractionated Radiation Therapy May Halve Treatment Time for Lung Cancer Patients With Poor Performance Status

For patients with stage II and III non–small cell lung cancer (NSCLC) unable to receive standard treatments of surgery or chemoradiation, hypofractionated radiation therapy results in similar overall survival and progression-free survival rates, limited severe side effects, and shorter...

Palliative Care
Supportive Care
Hematologic Malignancies

Areej El-Jawahri, MD, on Hematologic Malignancies: Integrating Palliative Care in Treatment


Nivolumab Achieves Response in Most Patients With Classical Hodgkin Lymphoma After ASCT and Brentuximab Vedotin

In a phase II trial reported in The Lancet Oncology by Anas Younes, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, treatment with the anti–PD-1 (programmed cell death protein 1) immune checkpoint inhibitor nivolumab (Opdivo) produced response in two-thirds of patients with...

President Obama Names Margaret Spitz, MPH, to National Cancer Advisory Board

Margaret Spitz, MPH, Professor in the National Cancer Institute (NCI)-designated Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, has been appointed by President Barack Obama as a member of the National Cancer Advisory Board (NCAB).

A renowned expert in molecular...

ASTRO 2016: SBRT Offers Patients With Prostate Cancer High Disease Control and Low Toxicity in Fewer Treatments

High-dose stereotactic body radiotherapy (SBRT) for men newly-diagnosed with low- or intermediate-risk prostate cancer results in shorter treatment times, low severe toxicity, and excellent cancer control rates, according to research presented by Meier et al at the 58th Annual Meeting of the

Palliative Care
Issues in Oncology

J. Nicholas Dionne-Odom, PhD, on Supporting Family Caregivers: The ENABLE Model

Hematologic Malignancies
Multiple Myeloma

Roundup of Selected Abstracts in Multiple Myeloma, Acute and Chronic Leukemia, and Advanced Lymphoma

In June 2016, the European Hematology Association Congress convened in Copenhagen, Denmark. The educational and scientific program highlighted state-of-the-art clinical practice and the latest findings in hematology research. The ASCO Post brings its readers brief summaries of some of the important ...


Patient-Reported Outcomes After Active Monitoring, Surgery, or Radiotherapy in PSA-Detected Localized Prostate Cancer

Patient-reported outcomes differed among men with localized prostate cancer detected by prostate-specific antigen (PSA) testing who were randomized to receive active monitoring, surgery, or radiotherapy in the UK ProtecT trial, according to a report by Donovan et al in The New England Journal of...

click me